New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk

A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial showed a significant 58.2% LDL-C reduction in patients already on statins, with mild side effects. This oral formulation simplifies cholesterol management, potentially improving adherence and access to treatment.

New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk
A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial showed a significant 58.2% LDL-C reduction in patients already on statins, with mild side effects. This oral formulation simplifies cholesterol management, potentially improving adherence and access to treatment.